BioTime CEO Dr. Michael West to Present at the Jefferies 2011 Global Healthcare Conference
June 02 2011 - 12:46PM
Business Wire
BioTime, Inc. (NYSE Amex: BTX) Chief Executive Officer, Michael
D. West, Ph.D., is scheduled to speak during the Jefferies 2011
Global Healthcare Conference June 6-9, 2011 in New York City. Dr.
West will present on Thursday, June 9 at 1:00 p.m. EDT. He will
discuss BioTime’s business in regenerative medicine and provide an
update on recent progress in developing its stem cell-based
products.
A link to the live webcast of the company’s presentation will be
available in the investors section of the BioTime website at
www.biotimeinc.com. A replay will be available on the BioTime
website for at least 30 days.
This investor conference hosted by Jefferies will feature a
keynote address by President Bill Clinton and informative
presentations from more than 300 leading public and private
healthcare companies across the healthcare service, life science,
medical technology, healthcare IT, and biopharmaceutical
sectors.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a
biotechnology company focused on regenerative medicine and blood
plasma volume expanders. Its broad platform of stem cell
technologies is developed through subsidiaries focused on specific
fields of applications. BioTime develops and markets research
products in the field of stem cells and regenerative medicine,
including a wide array of proprietary ACTCellerate™ cell lines,
culture media, and differentiation kits. BioTime's wholly owned
subsidiary ES Cell International Pte. Ltd. has produced
clinical-grade human embryonic stem cell lines that were derived
following principles of Good Manufacturing Practice and currently
offers them for use in research. BioTime's therapeutic product
development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a
high unmet medical need. BioTime's majority owned subsidiary Cell
Cure Neurosciences, Ltd. is developing therapeutic products derived
from stem cells for the treatment of retinal and neural
degenerative diseases. Cell Cure's minority shareholder Teva
Pharmaceutical Industries has an option to clinically develop and
commercialize Cell Cure's OpRegen™ retinal cell product for use in
the treatment of age-related macular degeneration. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic
applications of stem cells to treat orthopedic diseases and
injuries. Another subsidiary, OncoCyte Corporation, focuses on the
therapeutic applications of stem cell technology in cancer,
including using vascular progenitor cells engineered to destroy
malignant tumors. ReCyte Therapeutics, Inc. is developing
applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to
treat cardiovascular and blood cell diseases. BioTime's newest
subsidiary, LifeMap Sciences, Inc., is developing an online
database of the complex cell lineages arising from stem cells to
guide basic research and to market BioTime's research products. In
addition to its stem cell products, BioTime develops blood plasma
volume expanders, blood replacement solutions for hypothermic (low
temperature) surgery, and technology for use in surgery, emergency
trauma treatment and other applications. BioTime's lead product,
Hextend®, is a blood plasma volume expander manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corp. under exclusive licensing agreements. Additional
information about BioTime, ReCyte Therapeutics, Cell Cure,
OrthoCyte, OncoCyte, BioTime Asia, and ESI can be found on the web
at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for the company and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company's business,
particularly those mentioned in the cautionary statements found in
the company's Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0.
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2024 to Jun 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2023 to Jun 2024